Summary of Multiple Sclerosis (MS) Treatment Updates (from provided text)
Here’s a breakdown of the key updates in MS treatment, based on the provided text, categorized for clarity:
1. New & Ongoing Clinical trials:
* Ublituximab (NCT04130997): Phase 3, open-label extension study evaluating the long-term safety and efficacy of ublituximab in relapsing MS. Completion estimated: February 1, 2030.
* Fenebrutinib (NCT04544449): Phase 3 FENtrepid trial assessing fenebrutinib (a BTK inhibitor) against placebo in primary progressive MS. Completion estimated: December 18, 2026.
2. ocrelizumab (Ocrevus) – Dosage & Real-World Use:
* MUSETTE Trial (NCT04544436): Higher doses of ocrelizumab (1200mg/1800mg) did not demonstrate added benefit over the standard 600mg dose in slowing disability progression in relapsing MS. The 600mg dose remains optimal.Higher doses were well-tolerated.
* Real-World Data: Discontinuation rates of ocrelizumab are low (3.2%-4.1% for RRMS & PPMS) and comparable to those seen in clinical trials, suggesting good tolerability.
* Common reasons for discontinuation: side effects, concerns about efficacy, pregnancy/family planning.
* Ocrelizumab generally has higher adherence and lower discontinuation rates compared to other DMTs.
* Discontinuation rates due to side effects were higher than with rituximab, but overall first-year discontinuation rates were similar.
3. Emerging Treatments for Progressive MS:
* Bruton Tyrosine Kinase Inhibitors (BTKis): A promising class of drugs, particularly for progressive forms of MS.
* Tolebrutinib: Showed a substantial effect in slowing disability progression in non-relapsing secondary progressive MS. It crosses the blood-brain barrier and acts on B cells, macrophages, and microglia in the CNS.
* Fenebrutinib & Remibrutinib: Also showing potential in limiting lesion activity.
* Remyelination & Neuroprotection: Research is ongoing with compounds like clemastine fumarate and metformin.
In essence, the updates highlight continued research into both established treatments (like ocrelizumab) and novel therapies, with a particular focus on addressing the challenges of progressive MS.
